Adam Goulburn

Adam Goulburn is a venture capitalist and entrepreneur with extensive experience in the life sciences and healthcare technology sectors.12 He was formerly a Partner at Lux Capital, where he invested in companies at the intersection of biology, healthcare, technology, and data.24

Goulburn's educational background includes:

• PhD in Stem Cell Research from Monash University
• Bachelor of Commerce and Bachelor of Science in International Business, Accounting, and Biotechnology from the University of New South Wales14

His professional experience includes:

• Co-Founder of Dimension, a venture capital firm, since March 202213
• Partner at Lux Capital from October 2015 to March 20221
• Founding CEO of VNV Bio (now Aera Therapeutics) from October 2018 to January 20211
• Founding CEO of Kallyope from December 2014 to December 201512
• Post-Doctoral Associate in Neuroscience at Weill Cornell Medical College from August 2010 to November 201112

Goulburn has been involved in founding and incubating several companies, including Cajal Neuroscience, VNV Bio, and Kallyope.25 He has led investments in various healthcare technology companies, such as Science 37, RDMD, Rivet, Senti Biosciences, and Eikon Therapeutics.24

His investment interests include the digitization of healthcare, genomics, the microbiome, neuroscience, regenerative medicine, and other areas of applied hard sciences.25